Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
260M
-
Number of holders
-
3
-
Total 13F shares, excl. options
-
8.79M
-
Shares change
-
+8.79M
-
Total reported value, excl. options
-
$6.06M
-
Value change
-
+$6.06M
-
Number of buys
-
3
-
Price
-
$0.69
Significant Holders of SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) as of Q4 2023
3 filings reported holding SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2023.
SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) has 3 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.79M shares
of 260M outstanding shares and own 3.39% of the company stock.
Largest 3 shareholders include MARSHALL WACE, LLP (4.59M shares), RA CAPITAL MANAGEMENT, L.P. (2.37M shares), and COMMODORE CAPITAL LP (1.83M shares).
This table shows the top 3 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.